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The Subcutaneous Implantable Cardioverter-Defibrillator
Should Patients Want One?
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The subcutaneous implantable cardioverter-defibrillator is a novel device that does not require insertion of a
transvenous lead; rather, it delivers 80-J transthoracic shocks via a subcutaneous pulse generator implanted in
the left lateral chest and a subcutaneous left parasternal lead-electrode. It recently received approval by U.S.
Food and Drug Administration panel on the basis of a 180-day study in 330 patients. However, it has not been
shown to be non inferior to current implantable cardioverter-defibrillators, and it does not provide either anti-
tachycardia or bradycardia pacing. Thus, is this technology ready for widespread application? Specifically, should
a patient want one? (J Am Coll Cardiol 2013;61:20–2) © 2013 by the American College of Cardiology
Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.069The transvenous implantable cardioverter-defibrillator (T-ICD)
is a lifesaving device that has proven its safety and efficacy
during 3 decades of use in over 1 million patients. Multiple
clinical trials have established its benefit in diverse patient
populations for the primary and secondary prevention of
sudden cardiac death. Certainly lead problems and persis-
tent concerns with regard to costs and appropriate use are
real issues. Nevertheless, we currently have devices that are
reasonably reliable, cost-effective, and lifesaving. Now, a
new treatment option is on the horizon, the subcutaneous
implantable cardioverter-defibrillator (S-ICD) (1).
The proposed indication for an S-ICD is for patients who
are candidates for ICD insertion on the basis of current
guidelines and who do not have symptomatic bradycardia or
spontaneous, recurring ventricular tachycardia (VT) that is
reliably terminated with anti-tachycardia pacing (ATP).
The S-ICD consists of an electrically active pulse generator,
which is implanted near the left mid-axillary line (Fig. 1),
and a subcutaneous lead, consisting of sensing electrodes
and a shocking coil, which is tunneled 1 to 2 cm to the left
of the mid-sternal line. The S-ICD weighs 145 grams and
has a lithium battery with a projected life of 5 years; therapy
consists of 80-Joule (J) biphasic transthoracic shocks and
30 s of post-shock pacing. Given the available clinical data,
is the potentially simpler and safer S-ICD ready for wide-
spread use? Specifically, should patients want one?
In April 2012, the U.S. Food and Drug Administration
(FDA) Cardiovascular Device panel voted to approve the
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early 2013. The panel based its approval on the results of a
180-day prospective, single-arm, 330 patient multicenter
investigational device exemption (IDE) study and data from
previous studies and registries (2). The primary IDE safety
and efficacy endpoints were met, but the efficacy endpoint
did not test the ability of the S-ICD to terminate
spontaneous ventricular fibrillation (VF); rather, the
efficacy endpoint was based on successful detection and
termination of induced VF. This surrogate might be
appropriate for transvenous ICDs, but its applicability to
S-ICDs is unknown. Thus, by design, this study did not
demonstrate the efficacy of S-ICD in ambulatory pa-
tients. The most frequent adverse event was inappropri-
ate therapy, which affected 11.8% of patients, who
received unnecessary 80-J shocks.
Compared with S-ICDs, single chamber T-ICDs weigh
approximately one-half as much, have a longer battery life,
and they defibrillate transvenously with 40 J. Unlike the
S-ICD, the tiered therapy T-ICD provides 3 functions,
namely defibrillation, ATP, and bradycardia pacing. A large
proportion of ICD patients have VT that can be terminated
painlessly by ATP. Twenty years ago, a pivotal study of
tiered therapy ICDs concluded that the “most important
advance in device therapy is the option to treat monomor-
phic ventricular tachycardia with antitachycardia pacing
maneuvers” (3). Without ATP, a conscious patient will
receive painful 80-J shocks for VT. But it is often difficult to
determine which primary prevention patients will develop
VT. In the MADIT-II (Multicenter Automatic Defibrilla-
tion Trial), 25% of patients—who were not inducible in the
electrophysiological testing arm—experienced a clinical VT
episode within the first 3 years after implant (4). Indeed, in
the S-ICD IDE study, even though patients with known
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who had a spontaneous VT/VF event during follow-up
received an 80-J shock for monomorphic VT. Moreover,
although controversial, current data suggest that all T-ICD
shocks, both appropriate and inappropriate, might be asso-
ciated with reduced longevity and quality of life (5). Thus,
ATP might confer important advantages that are not
available in shock-only devices.
But there is another, even larger issue: the S-ICD has not
yet been shown to be safe and effective in a diverse patient
population, and it has not yet been shown to be non inferior
to T-ICDs. Implantable defibrillators are lifesaving devices;
T-ICDs perform this function reliably. Any new device
introduced for a similar indication must perform compara-
bly to current ICD systems, because the consequences of
inferior performance are not tolerable. Although the results
of the IDE study are encouraging, the critical question is:
can we inform patients during the consent process on the
basis of current knowledge that the S-ICD and T-ICD are
equivalent therapies? Or, is the S-ICD the better choice?
The answer is there are no data showing equivalency—
much less superiority—in patients at high risk for sudden
cardiac death.
Unless critical questions with regard to safety and efficacy
in primary and secondary prevention are addressed, the
S-ICD should be confined to certain subgroups. These
include individuals without venous access and who are poor
candidates for thoracotomy that might be suitable for an
S-ICD. Similarly, patients who are at high risk for devel-
Figure 1 Subcutaneous Implantable Cardioverter-Defibrillator
The electrically active pulse generator is implanted near the left mid-axillary
line, and the subcutaneous lead-electrode is tunneled 1 to 2 cm to the left of
the mid-sternal line.oping sepsis with an intravascular
device might be best served with
an S-ICD. It has been suggested
that young patients who have
hereditary heart disease might be
candidates for an S-ICD, be-
cause transvenous leads are prone
to failure in children and active
adults; this would be a legitimate
argument if we could be confi-
dent the S-ICD can provide life-
saving therapy for such patients,
most of whom have a good prog-
nosis if sudden cardiac death can
be avoided.
Beyond these discrete scenar-
ios, the immediate use of
S-ICDs ought to be limited.
The need for more data with this promising device
should be paramount at this time. We should seize the
opportunity to do the appropriate comparative effective-
ness research in multiple patient cohorts. Although it can
be argued that such an approach might stifle innovation,
there is no reason to lower the bar for an FDA Class 3
device (devices that support or sustain human life, are of
substantial importance in preventing impairment of hu-
man health, or which present a potential, unreasonable
risk of illness or injury). The requirement for data
supporting safety and efficacy in Class 3 devices should
remain absolute when a new device like the S-ICD is
intended for patients who can be treated with an ap-
proved device (e.g., the T-ICD) that has been shown to
be safe and effective.
History has taught us that there should be no shortcuts in
bringing life-supporting or life-sustaining products to mar-
ket. If the FDA approves the S-ICD on the basis of the
IDE study results, there will be no incentive for the
manufacturer or independent investigators to sponsor or
support a trial where the S-ICD is compared with the
T-ICD. However, the FDA should consider conditional
approval, which would allow the S-ICD to be used in the
context of clinical trials that are designed to assess its safety
and efficacy.
The S-ICD is a promising technology that could fill a gap
in the treatment of ventricular tachyarrhythmias by extend-
ing this vital therapy to patients in countries where the
facilities to implant T-ICDs are not available. Indeed, if this
new device that is based on simplicity and ease of implan-
tation can be deployed at less cost and with non inferior
clinical outcomes, it could become a breakthrough therapy.
But it is a new technology and, as such, requires the scrutiny
of a comparative effectiveness trial. Only then can we tell
patients that it is as effective as existing ICDs. Otherwise, a
fully informed patient who is offered this device today
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